rp 73401 has been researched along with Fibrosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hazama, M; Hirozane, Y; Matsuo, T; Muraki, Y; Nio, Y; Okawara, M; Tanaka, M | 1 |
| Dunkern, TR; Feurstein, D; Hatzelmann, A; Rossi, GA; Sabatini, F | 1 |
2 other study(ies) available for rp 73401 and Fibrosis
| Article | Year |
|---|---|
Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Benzamides; Fibrosis; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Contraction; Muscle, Skeletal; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; PPAR gamma; Pyridines; RNA, Messenger; Sildenafil Citrate | 2017 |
Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase.
Topics: Actins; Benzamides; Benzoates; Blotting, Western; Cell Differentiation; Cells, Cultured; Cyclic GMP; Dinoprostone; Drug Synergism; Enzyme Activators; Fibroblasts; Fibrosis; Guanylate Cyclase; Humans; Immunohistochemistry; Isoenzymes; Lung; Myocytes, Smooth Muscle; Natriuretic Peptide, Brain; Nitric Oxide Donors; Nitroso Compounds; Oxadiazoles; Phosphodiesterase Inhibitors; Piperazines; Purines; Pyridines; Quinoxalines; Receptors, Cytoplasmic and Nuclear; Sildenafil Citrate; Soluble Guanylyl Cyclase; Sulfones; Transforming Growth Factor beta | 2007 |